ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstracts tagged "cost containment and rheumatoid arthritis (RA)"

  • Abstract Number: 2439 • 2017 ACR/ARHP Annual Meeting

    Switching from RA Originator to Biosimilar in Routine Clinical Care:  Early Data from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis

    Diederik De Cock1, Lianne Kearsley-Fleet1, Kath Watson1 and Kimme L. Hyrich1,2, 1Arthritis Research UK Centre for Epidemiology, University of Manchester, Manchester Academic Health Science Centre, Manchester, United Kingdom, 2National Institute of Health Research Manchester Musculoskeletal Biomedical Research Centre, Central Manchester NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom

    Background/Purpose: Biosimilars, biopharmaceuticals assessed by regulatory agencies to have efficacy and safety similar to their reference products, were introduced to the UK market in February…
  • Abstract Number: 1999 • 2016 ACR/ARHP Annual Meeting

    Claims-Based Analysis of Cost-Effectiveness Among Patients with Rheumatoid Arthritis Who Switched from a Tumor Necrosis Factor Inhibitor to Another Targeted Disease-Modifying Antirheumatic Drug

    Machaon Bonafede1, Wenhui Wei2, Chieh-I Chen3, Donna McMorrow1, Stefano Fiore4, Jonathan Fay3, Toshio Kimura3 and Jeffrey R. Curtis5, 1Truven Health Analytics, Cambridge, MA, 2Sanofi US, Inc., Bridgewater, NJ, 3Regeneron Pharmaceuticals, Inc., Tarrytown, NY, 4Sanofi Genzyme, Bridgwater, NJ, 5Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL

    Background/Purpose: Patients with rheumatoid arthritis (RA) who have an inadequate response to a tumor necrosis factor inhibitor (TNFi) can switch to another targeted disease-modifying antirheumatic…
  • Abstract Number: 617 • 2015 ACR/ARHP Annual Meeting

    Biological Down-Titration in RA: Patient Profile and Response to Retreatment in Flaring Patients

    Juan P. Vinicki1, Miguel Arredondo1, Esther Ramirez2, Ana M. Ortiz Garcia3, Santos Castañeda4, Alberto Morell1, Rosario Garcia-Vicuña3 and Jose María Alvaro-Gracia4, 1Unidad de Terapias Biológicas, Hospital Universitario de La Princesa. IIS La Princesa, Madrid, Spain, 2Farmacia, Hospital Universitario de La Princesa. IIS La Princesa, Madrid, Spain, 3Rheumatology, Hospital Universitario de La Princesa. IIS La Princesa, Madrid, Spain, 4Hospital Universitario de La Princesa. IIS La Princesa, Madrid, Spain

    Background/Purpose: Down-titration of biological therapy (BT) in rheumatoid arthritis (RA) patients with a good clinical response is frequently applied in daily clinical practice. An important…
  • Abstract Number: 1166 • 2014 ACR/ARHP Annual Meeting

    5 Year Budget Impact Analysis of Biosimilar Infliximab for the Treatment of Rheumatoid Arthritis in UK, Italy, France and Germany

    JiSeon Kim1, JungAn Hong1 and Alex Kudrin2, 1CELLTRION HEALTHCARE, INCHEON, South Korea, 2CELLTRION, Inc., Incheon, South Korea

    Background/Purpose: Biosimilar infliximab has been approved by EMA based on comparable quality, safety and efficacy profile to infliximab for the management of inflammatory autoimmune disorders…
  • Abstract Number: 481 • 2013 ACR/ARHP Annual Meeting

    Down-Titration of Biological Therapies In Rheumatoid Arthritis In Daily Clinical Practice

    Miguel Arredondo1, Iciar Cañamares2, Esther Ramírez-Herráiz2, Isidoro Gonzalez-Alvaro3, Alberto Garcia-Vadillo3, Alberto Morell1, Rosario Garcia-Vicuña4 and Jose María Alvaro-Gracia5, 1Unidad de Terapias Biológicas, Hospital Universitario de La Princesa. IIS La Princesa, Madrid, Spain, 2Servicio de Farmacia, Hospital Universitario de La Princesa, Madrid, Spain, 3Servicio de Reumatología, Hospital Universitario de La Princesa, Madrid, Spain, 4Rheumatology, Hospital Universitario de La Princesa. IIS La Princesa, Madrid, Spain, 5Unidad de Terapias Biológicas. Servicio de Reumatología, Hospital Universitario de La Princesa, Madrid, Spain

    Background/Purpose: One of the limiting factors for the use of biological therapies (BT) is cost. For this reason, the development of cost optimization strategies without…
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences